The hypothesis on which this proposal is based is that intracellular signalling pathways mediating the effects of growth factors and oncogenes represent logical target sites at which to direct new anticancer drug development to exploit basic biochemical differences between normal and tumor cells for the treatment of cancer. Because natural products from higher plants and algae provide a potentially rich source of new and novel chemical compounds, we have decided to concentrate our efforts to discover now mechanism based anticancer agents in this area.
The specific aims of the proposal are: 1. To isolate and identify, through bioassay directed fractionation, new compounds with novel chemical structures from higher plants and algae that act on growth factor and oncogene signal transduction pathways, and exhibit in vitro cytotoxicity. 2. To chemically modify existing active compounds such as staurosporine, erbstatin and suramin and newly discovered compounds to improve their selective cytotoxicity and activity against tumor call signal transduction targets. 3. To develop and utilize the following signal transduction targets for identifying potential anticancer agents; a) alterations in intracellular free Ca2+ regulation b) modulation of protein kinase C activity c) inhibition of protein tyrosine kinase activity 4. To conduct, in conjunction with Specific Aim 3) above, selective in vitro cytotoxicity studies using cultured human solid tumor cell lines. 5. Evaluate in vivo antitumor efficacy of active compounds from 4) above in appropriate mouse and human xenograft tumor models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA052995-06S1
Application #
3731079
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Ihle, N T; Powis, G; Kopetz, S (2011) PI-3-Kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets 11:190-8
Liu, Enbo; Knutzen, Christine A; Krauss, Sybille et al. (2011) Control of mTORC1 signaling by the Opitz syndrome protein MID1. Proc Natl Acad Sci U S A 108:8680-5
Gwak, Ho-Shin; Shingu, Takashi; Chumbalkar, Vaibhav et al. (2011) Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128:787-96
Leone, Marilisa; Barile, Elisa; Vazquez, Jesus et al. (2010) NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH. Chem Biol Drug Des 76:10-6
Ihle, Nathan T; Powis, Garth (2010) The biological effects of isoform-specific PI3-kinase inhibition. Curr Opin Drug Discov Devel 13:41-9
Koul, Dimpy; Shen, Ruijun; Kim, Yong-Wan et al. (2010) Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12:559-69
Ihle, Nathan T; Powis, Garth (2010) Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 31:135-44
Ihle, Nathan T; Lemos, Robert; Schwartz, David et al. (2009) Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 8:94-100
Ihle, Nathan T; Lemos Jr, Robert; Wipf, Peter et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-50
Katiyar, Samiksha; Liu, Enbo; Knutzen, Christine A et al. (2009) REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep 10:866-72

Showing the most recent 10 out of 14 publications